Tedizolid (TR-701): a new oxazolidinone with enhanced potency.
INTRODUCTION: Tedizolid phosphate (TR-701) is a new oxazolidinone prodrug that is transformed in the serum into the active drug tedizolid (TR-700). Tedizolid acts by inhibiting protein synthesis and has broad activity against Gram-positive pathogens, including strains that are resistant to linezolid. AREAS COVERED: This review summarizes the currently available data on this new antimicrobial agent. In vitro activity, pharmacokinetics/pharmacodynamics, clinical efficacy and safety are all addressed. EXPERT OPINION: Tedizolid will provide a useful addition to the antimicrobial armamentarium, particularly in complicated skin and skin structure infections, due to its high oral bioavailability and once-daily dosing. The results of future studies will serve to better position tedizolid among the newly approved agents for infections caused by Gram-positive organisms.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Tetrazoles
- Randomized Controlled Trials as Topic
- Protein Synthesis Inhibitors
- Pharmacology & Pharmacy
- Oxazolidinones
- Humans
- Gram-Positive Bacteria
- Clinical Trials as Topic
- Anti-Bacterial Agents
- Animals
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Tetrazoles
- Randomized Controlled Trials as Topic
- Protein Synthesis Inhibitors
- Pharmacology & Pharmacy
- Oxazolidinones
- Humans
- Gram-Positive Bacteria
- Clinical Trials as Topic
- Anti-Bacterial Agents
- Animals